Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zotatifin Phase 1-2 Study in Advanced Solid Tumors
NCT04092673Phase 2Recruiting
- Sponsor
- eFFECTOR Therapeutics
- Start
- Oct 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zotatifin in breast cancer, non-small cell lung cancer (NSCLC), solid tumor, sponsored by eFFECTOR Therapeutics. Started Oct 2019; status: recruiting.
02
Drugs
zotatifin
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04092673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092673.